Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 6.5% - Time to Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) rose 6.5% during mid-day trading on Wednesday . The stock traded as high as $5.25 and last traded at $5.16. Approximately 14,759,864 shares were traded during trading, a decline of 3% from the average daily volume of 15,162,708 shares. The stock had previously closed at $4.84.

Analyst Ratings Changes

RXRX has been the subject of several analyst reports. Needham & Company LLC cut their price target on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. Cowen restated a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Morgan Stanley cut their price target on shares of Recursion Pharmaceuticals from $8.00 to $5.00 and set an "equal weight" rating for the company in a research report on Monday. Finally, Leerink Partners cut their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research report on Friday, February 28th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $7.00.

Recursion Pharmaceuticals Trading Up 6.7%

The firm has a market cap of $2.10 billion, a PE ratio of -2.92 and a beta of 0.84. The company has a quick ratio of 4.11, a current ratio of 4.11 and a debt-to-equity ratio of 0.02. The stock's fifty day simple moving average is $4.91 and its two-hundred day simple moving average is $6.30.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). The business had revenue of $14.75 million during the quarter, compared to analysts' expectations of $18.12 million. Recursion Pharmaceuticals had a negative return on equity of 74.70% and a negative net margin of 961.32%. Recursion Pharmaceuticals's revenue for the quarter was up 7.2% compared to the same quarter last year. During the same quarter last year, the company posted ($0.39) EPS. On average, sell-side analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the company. Ensign Peak Advisors Inc boosted its holdings in Recursion Pharmaceuticals by 0.3% in the fourth quarter. Ensign Peak Advisors Inc now owns 410,286 shares of the company's stock worth $2,774,000 after purchasing an additional 1,300 shares during the last quarter. Farther Finance Advisors LLC boosted its stake in shares of Recursion Pharmaceuticals by 21.1% during the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock worth $52,000 after acquiring an additional 1,353 shares during the last quarter. Summit Investment Advisors Inc. boosted its stake in shares of Recursion Pharmaceuticals by 7.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 26,030 shares of the company's stock worth $176,000 after acquiring an additional 1,875 shares during the last quarter. Clear Creek Financial Management LLC raised its position in shares of Recursion Pharmaceuticals by 9.8% during the 1st quarter. Clear Creek Financial Management LLC now owns 21,315 shares of the company's stock valued at $113,000 after purchasing an additional 1,907 shares during the period. Finally, GAMMA Investing LLC increased its holdings in Recursion Pharmaceuticals by 39.0% in the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock valued at $38,000 after acquiring an additional 2,026 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company's stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.